Effect of tight control of HbA1c and blood pressure on cardiovascular diseases in type 2 diabetes: An observational study from the Swedish National Diabetes Register (NDR)

Diabetes Research and Clinical Practice

Volumn 86, Issue 1, 2009, Pages 74-81

  Cederholm, Jan ^a   Zethelius, Björn ^a   Nilsson, Peter M ^b   Eeg Olofsson, Katarina ^c   Eliasson, Björn ^c   Gudbjörnsdottir, Soffia ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Blood pressure; Cardiovascular diseases; Diabetes; Myocardial infarction; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DISEASE DURATION; DRUG USE; FEMALE; FOLLOW UP; GENDER; HAZARD RATIO; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REGISTER; RISK REDUCTION; SMOKING; STROKE; SWEDEN;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 69849089051     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.07.003     Document Type: Article

References (38)

1. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
2. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998) 823-828
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type-2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
4. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
5. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Lancet 355 (2000) 253-259
6. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch. Intern. Med. 165 (2005) 1410-1419
7. Patel A., MacMahon S., Chalmers J., Neal B., Woodward M., Billot L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007) 829-840
8. Avogaro A., Giorda C., Maggini M., Mannucci E., Raschetti R., Lombardo F., et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 30 (2007) 1241-1247
9. Gerstein H.C., Pogue J., Mann J.F., Lonn E., Dagenais G.R., McQueen M., et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48 (2005) 1749-1755
10. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
11. Selvin E., Marinopoulos S., Berkenblit G., Rami T., Brancati F.L., Powe N.R., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 141 (2004) 421-431
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
14. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359 (2008) 1577-1589
15. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008) 2545-2559
16. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008) 2560-2572
17. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med. 360 (2009) 129-139
18. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 358 (2008) 580-591
19. Gudbjörnsdottir S., Cederholm J., Nilsson P.M., and Eliasson B. The National Diabetes Register in Sweden: an implementation of the St. Vincent declaration for quality improvement in diabetes care. Diabetes Care 26 (2003) 1270-1276
20. Cederholm J., Eliasson B., Nilsson P.M., Weiss L., Gudbjörnsdottir S., and for the steering committee of the Swedish National Diabetes Register. Microalbuminuria and risk factors in type 1 and type 2 diabetic patients. Diabetes Res. Clin. Pract. 67 (2005) 258-266
21. Eliasson B., Cederholm J., Nilsson P., Gudbjörnsdottir S., and for the steering committee of the Swedish National Diabetes Register. The gap between guidelines and reality: Type 2 diabetes in a national diabetes register 1996-2003. Diabet. Med. 22 (2005) 1420-1426
22. Nilsson P.M., Cederholm J., Gudbjörnsdottir S., Eliasson B., and for the Steering Committee of the Swedish National Diabetes Register. Predictors of successful long-term blood pressure control in patients with diabetes-data from the Swedish National Diabetes Register (NDR). J. Hypertens. 23 (2005) 2305-2311
23. Cederholm J., Eeg-Olofsson K., Eliasson B., Zethelius B., Nilsson P.M., Gudbjörnsdottir S., et al. Risk prediction of cardiovascular disease in type 2 diabetes. Diabetes Care 31 (2008) 2038-2043
24. Eeg-Olofsson K., Cederholm J., Nilsson P.M., Zethelius B., Nunez L., Gudbjörnsdottir S., et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13.087 patients. Diabetologia 52 (2009) 65-73
25. Hoelzel W., Weykamp C., Jeppsson J.O., Miedema K., Barr J.R., Goodall I., et al. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin. Chem. 1 (2004) 166-174
26. Merlo J., Lindblad U., Pessah-Rasmussen H., Hedblad B., Rastam J., Isacsson S.O., et al. Comparison of different procedures to identify probable cases of myocardial infarction and stroke in two Swedish prospective cohort studies using local and national routine registers. Eur. J. Epidemiol. 16 (2000) 235-243
27. Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., and Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, events rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 90 (1994) 583-612
28. Spiegelman D., Hertzmark E., and Wand H.C. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. Cancer Causes Control 18 (2007) 571-579
29. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur. Heart J. 28 (2007) 88-136
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
31. Intensive BP and glucose-lowering additive in diabetics: ADVANCE, http://www.theheart.org/article/902457.do, September 8, 2008.
32. Saydah S.H., Fradkin J., and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 291 (2004) 335-342
33. Gudbjörnsdottir S., Eeg-Olofsson K., Cederholm J., Zethelius B., Eliasson B., and Nilsson P.M. Risk factor control in patients with type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet. Med. 26 (2009) 53-60
34. Lind L., Lithell H., and Pollare T. Is it hyperinsulinemia or insulin resistance that is related to hypertension and other metabolic cardiovascular risk factors?. J. Hypertens. 11 Suppl. (1993) S11-S16
35. Sung K.C., Kim B.J., Kim B.S., Kang J.H., Lee M.H., Park J.R., et al. In normoglycemic Koreans, insulin resistance and adipocity are independently correlated with high blood pressure. Circ. J. 8 (2004) 898-902
36. Pollare T., Lithell H., and Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 39 (1990) 167-174
37. Mogensen C.E. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J. Intern. Med. 254 (2003) 45-66
38. Parving H.-H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345 (2001) 870-876